RWD283 COST-EFFECTIVENESS ANALYSIS OF DURVALUMAB AND ATEZOLIZUMAB WITH CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR FIRST-LINE TREATMENT OF EXTENSIVE-STAGE SMALL-CELL LUNG CANCER IN TAIWAN
Abstract
Authors
Shu-Hua Chan Ming-Neng Shiu